FIA
PTPI

FNY Investment Advisers’s Petros Pharmaceuticals PTPI Stock Holding History

FNY Investment Advisers’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-80
Closed -$73K – 933
2021
Q1 		$73K Buy
+80
New +$75.4K 0.03% 377

Other funds holding PTPI

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFAS
Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FNY Investment Advisers's PTPI Position: Q2 2021 in Review

FNY Investment Advisers sold out of Petros Pharmaceuticals (PTPI) in Q2 2021, closing a stake of 80 shares — an estimated $73K sold.

FNY Investment Advisers first reported a position in PTPI in Q1 2021 and held it in 1 quarter. The position peaked at $73K in Q1 2021. 18 funds tracked by Wall St. Rank hold PTPI as of Q2 2021.

  • FNY Investment Advisers reported no remaining Petros Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 80 Petros Pharmaceuticals shares in Q2 2021, an estimated $73K.
  • FNY Investment Advisers first reported a position in Petros Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Petros Pharmaceuticals position peaked at $73K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2021.

Based on FNY Investment Advisers's 13F filing for Q2 2021, filed 14 Jul 2021.